Future directions of osteoanabolic therapies in osteoporosis: Integrating current anabolic agents and emerging senescence-targeted strategies.

Authors

Hannah W Brooks, Nicholas C Cusick, Shuang Wu, Joshua N Farr

Published in

Best practice & research. Clinical rheumatology. Pages 102203. Oct 01, 2026. Epub Oct 01, 2026.

Abstract

Osteoporosis therapeutics have advanced from antiresorptive drugs that slow bone loss to osteoanabolic and dual-action agents that can rapidly rebuild skeletal integrity and reduce fracture risk. Yet the current anabolic era leaves important clinical questions unresolved: why responses vary among older adults, why gains are transient, how best to sequence therapy, and how to sustain skeletal resilience in the biologically aged bone microenvironment. Cellular senescence has emerged as a plausible mechanistic bridge linking skeletal aging, chronic inflammation, impaired osteoblastogenesis, increased osteoclastogenesis, marrow adiposity, diabetes-associated fragility, and delayed repair. Preclinical studies show that senescent-cell clearance can prevent or partially reverse age-related bone loss, while early human senolytic data suggest that skeletal response may depend on baseline senescent-cell burden. This review discusses current anabolic therapies, the rationale for senescence-targeted approaches, and future biomarker-informed strategies to integrate anabolic induction, antiresorptive consolidation, and experimental modulation of skeletal aging biology.

PMID:
42823204
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.